MICROB-PREDICT highlights at EASL Congress 2023
MICROB-PREDICT aims to identify microbiome-based biomarkers and mechanisms that predict in advance when the body can no longer compensate for the dysfunctional liver (decompensated cirrhosis), when such decompensated cirrhosis will progress to…
LITMUS highlights at EASL Congress 2023
Liver Investigation: Testing Marker Utility in Steatohepatitis (LITMUS) funded by the European Innovative Medicines Initiative 2 Joint Undertaking, brings together clinicians and scientists from prominent academic centres across Europe with companies from…
EASL Studio Special Episode “Promoting Liver Health: an urgent call for action at WHO”
On 22 May 2023, policymakers, thought leaders, Permanent Mission Representatives to the UN, WHO staff, and people affected by liver disease will gather at the EASL Office in Geneva for the invitation-only…
New EASL-ILCA CPGs on the management of intrahepatic cholangiocarcinoma
EASL is pleased to announce the release of the EASL-ILCA clinical practice guidelines on the management of intrahepatic cholangiocarcinoma to coincide with the EASL Liver Cancer Summit 2023. Intrahepatic cholangiocarcinoma (iCCA) represents…
Happy World Liver Day 2023! Get involved and help us celebrate it!
Join the global movement. Celebrate World Liver Day with us on 19 April 2023! We are excited to announce World Liver Day, taking place TODAY, 19 April 2023. This global movement led by the European…
Tribute to Prof. Peter Ferenci (1948-2023)
Dear colleagues and friends: We have to share the sad news that Peter Ferenci has passed away on 11 April 2023 just a few weeks before his 75th birthday. He recently celebrated…
Diagnosis of fatty liver in children should occur in parallel to investigation for other causes of liver disease
The European Association for the Study of the Liver (EASL) and the Society for Paediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN) have issued a joint statement on metabolic dysfunction-associated fatty liver disease (MAFLD),…